Reviewing NGM Biopharmaceuticals Inc. (NGM)’s and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s results

Since NGM Biopharmaceuticals Inc. (NASDAQ:NGM) and Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NGM Biopharmaceuticals Inc. 14 0.00 21.67M -0.07 0.00
Conatus Pharmaceuticals Inc. N/A -0.02 32.59M -0.57 0.00

Table 1 highlights NGM Biopharmaceuticals Inc. and Conatus Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
NGM Biopharmaceuticals Inc. 160,281,065.09% 0% 0%
Conatus Pharmaceuticals Inc. 9,449,115,685.71% -81% -32.8%

Liquidity

The Current Ratio and a Quick Ratio of NGM Biopharmaceuticals Inc. are 4.6 and 4.6. Competitively, Conatus Pharmaceuticals Inc. has 2.4 and 2.4 for Current and Quick Ratio. NGM Biopharmaceuticals Inc.’s better ability to pay short and long-term obligations than Conatus Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for NGM Biopharmaceuticals Inc. and Conatus Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NGM Biopharmaceuticals Inc. 0 0 1 3.00
Conatus Pharmaceuticals Inc. 0 0 0 0.00

The upside potential is 43.03% for NGM Biopharmaceuticals Inc. with average price target of $24.

Institutional & Insider Ownership

NGM Biopharmaceuticals Inc. and Conatus Pharmaceuticals Inc. has shares held by institutional investors as follows: 45.5% and 25.1%. 1.4% are NGM Biopharmaceuticals Inc.’s share held by insiders. Competitively, 3.34% are Conatus Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NGM Biopharmaceuticals Inc. 4.22% -2.76% -11.68% 0% 0% -4.29%
Conatus Pharmaceuticals Inc. -9.55% 17.93% -61.64% -86.16% -91.73% -81.6%

For the past year NGM Biopharmaceuticals Inc.’s stock price has smaller decline than Conatus Pharmaceuticals Inc.

Summary

NGM Biopharmaceuticals Inc. beats on 8 of the 11 factors Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.